 |
|
|||||||||||||||||
Table of ContentsThe Search For Novel Antidepressants- Pp. iAndre F. Carvalho, Gislaine Z. Réus and João Quevedo Download Free List of Contributors- Pp. iii-iv (2)Andre F. Carvalho, Gislaine Z. Reus and João Quevedo Download Free Innovative Solutions to the Development of Novel Antidepressants- Pp. 1-40 (40)Daniela Felice, Alain M. Gardier, Connie Sanchez and Denis J. David View Abstract Purchase Chapter Animal Models of Depression: Current Status and Perspectives- Pp. 41-76 (36)Morgana Moretti, Manuela P. Kaster and Ana Lúcia S. Rodrigues View Abstract Purchase Chapter Potential Role of Optogenetics for The Development of Novel Antidepressants- Pp. 77-98 (22)T. Chase Francis and Mary Kay Lobo View Abstract Purchase Chapter The Relevance of Studies in Healthy Human Volunteers for The Development of Novel Antidepressants: Exploring Endophenotypes- Pp. 99-125 (27)Renato T. Ramos View Abstract Purchase Chapter Monoamine Oxidase-A: A Valid Target for the Management of Depression- Pp. 126-134 (9)Bijo Mathew and Jerad Suresh View Abstract Purchase Chapter Repurposed Drugs: A Shortcut to the Discovery of Novel Antidepressants?- Pp. 135-176 (42)Young Sup Woo, Yena Lee and Roger S. McIntyre View Abstract Purchase Chapter Ketamine and Glutamatergic Compounds: Exploring Biomarkers and Mechanisms Related to Rapid Antidepressant Action- Pp. 177-200 (24)Gislaine Z. Réus, Helena M. Abelaira, Gerard Sanacora and João Quevedo View Abstract Purchase Chapter Novel Antidepressant Targets for Cognitive Dysfunction in Major Depressive Disorder- Pp. 201-221 (21)Beatrice Bortolato and Andre F. Carvalho View Abstract Purchase Chapter Oxidative and Nitrosative Stress, Immune Inflammation and Trptophan Catabolites in Driving Melatonergic Pathway Alterations in Depression: Treatment Implications- Pp. 222-241 (20)George Anderson and Michael Maes View Abstract Purchase Chapter Novel Non-Monoaminergic Antidepressants: Focus on Neuropeptides- Pp. 242-255 (14)Donatella Marazziti, Federico Mucci, Stefano Baroni and Liliana Dell`Osso View Abstract Purchase Chapter Novel Antidepressant Drugs: Exploring Neurotrophins and Intracellular Signaling Pathways- Pp. 256-297 (42)Gianluca Serafini, Admena Rreshketa, Maurizio Pompili, Paolo Girardi, Goutam Brahmachari and Mario Amore View Abstract Purchase Chapter Shared Pathophysiology between Depression, Obesity and Metabolic Disturbances: Novel Antidepressant Targets?- Pp. 298-356 (59)Léa Décarie-Spain, Dominique Matthys and Stephanie E. Fulton View Abstract Purchase Chapter The Development of Novel Antidepressants: Focus on Plant-based Drugs- Pp. 357-390 (34)Abir T. El-Alfy View Abstract Purchase Chapter ForewordIn spite of the undeniable progress of Psychiatry over the past 60 years, and hundreds of new molecules having been tested for the treatment of mental disorders, the pharmacological treatment of depression is far from being satisfactory. In the last decades, no significant paradigm shifts in the psychopharmacology of mood disorders have occurred, mostly because the development of novel antidepressant agents is limited by our limited understanding of the pathophysiology of the illness. In this context, Andre F. Carvalho, Gislaine Z. Reus, and João Quevedo have devoted their talent and effort to provide us with a crisp summary of the past, present, and future treatment options for the management of depression that will please both preclinical and clinical investigators in neuropsychopharmacology. This e-jewell, rather than e-book, (and its printed version) gathers prominent researchers in basic and clinical psychopharmacology, authoring thoughtful chapters on exciting topics such as animal models, optogenetics, endophenotypes, repurposing, cognitive dysfunction, biomarkers, oxidative stress, and the microbiota-brain axis, which are outstandingly relevant for understanding the current approach to the pathopshysiology of mood disorders. Modern and traditional treatment targets, such as glutamate receptors, monoamine-oxidase-A, intracellular signaling pathways, and new avenues based on the comorbidity between depression and metabolic syndrome, neuropeptides, or herbal remedies are also part of this comprehensive text which starts with a wonderful chapter on innovative solutions for the development of new antidepressant drugs. I personally enjoyed reading it and learnt much from it. In difficult times such as ours, when social and methodological hurdles are challenging our ability to translate scientific progress into true impactful innovation in this field, the reading of this book fuels fresh air into the community of scientists, clinicians, and perhaps informed patients who await answers or at least better questions for the understanding and management of depression.
Eduard Vieta, MD, PhD
PrefaceThis eBook was conceived after an invitation by the Bentham Science Publishers due to the necessity to review novel antidepressant alternatives. The prevalence of people with major depressive disorder (MDD) has increased drastically worldwide. In addition, many patients do not respond to classic antidepressant treatments. However, in the last years, new strategies have been studied in experimental and clinical approaches. The development of novel treatment of MDD would decrease the morbidity and mortality, and consequently the economic burden associated with hospital. Some of these new treatment alternatives are associated with a fast antidepressant effects and low side effects compared to classical treatments. Several studies indicate that pathological mechanisms involved with MDD development are not only based on monoaminergic system, but also with metabolic disturbances, inflammation and a decrease in protein involved with neuroplasticity. This eBook aims to contribute to an integrated understanding concerning innovative alternatives to treat MDD. It is based on cutting edge research and the outcome will shed light on the most appropriate approach to treat resistant-treatment MDD patients. It gathers a wide range of topics on the subject and includes several chapters with original material. Authors and co-authors represent a multidisciplinary team that includes scientists and professors with a vast experience in the area, from different universities and research institutions. It is an attempt to encourage the implementation of alternative approaches to the classic antidepressants for humans. The eBook is organized in fourteen chapters: the general introduction is followed by a review devoted to experimental models, optogenetics therapy, the role of healthy human volunteers, monoamine oxidase-A, repurposed drugs, glutamatergic compounds, cognition, oxidative and nitrosative stress, melatoninergic pathway, neuropeptides, gut microbiota, metabolic disturbances, and plant-based drugs. Ultimately, we would like to thank all authors that have actively contributed to this eBook, and all people that someway helped us to bring it to daylight, including our family, friends, students and colleagues.
Andre F. Carvalho
List of ContributorsEditor(s):Andre F. CarvalhoAssociate Professor of Psychiatry Head, Translational Psychiatry Research Group Faculty of Medicine Federal University of Ceara Fortaleza, CE Brazil Gislaine Zilli Reus Laboratory of Neurosciences University of Southern Santa Catarina 1105 - Av Universitaria Brazil João Luciano de Quevedo Center for Translational Psychiatry Department of Psychiatry and Behavioral Sciences Medical School, The University of Texas Health Science Center at Houston Houston, TX USA Contributor(s):Abir T. El-AlfyDepartment of Pharmaceutical Sciences, College of Pharmacy, Chicago State University, Chicago, IL, USA Admena Rreshketa Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry University of Genoa Italy Alain M. Gardier Institut National de la Santé et de la recherche Médicale UMR-S 1178 Santé Mentale et Santé Publique, Univ. Paris-Sud, Fac Pharmacie, Université Paris Saclay Châtenay-Malabry France Ana Lúcia S. Rodrigues Department of Biochemistry, Center of Biological Sciences Universidade Federal de Santa Catarina, Campus Universitário, Florianópolis, SC Brazil Andre F. Carvalho Department of Clinical Medicine and Psychiatry Research Group Faculty of Medicine, Federal University of Ceara, Fortaleza, CE Brazil Beatrice Bortolato Department of Mental Health, ULSS 10 “Veneto Orientale” Venice Italy Bijo Mathew Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy Division of Drug Design and Medicinal Chemistry Research Lab Palakkad, Kerala India Connie Sanchez Lundbeck Research USA, Inc., 215 College Road, 07652 Paramus, NJ United States Daniela Felice Univ. Paris-Sud, Fac Pharmacie, Université Paris Saclay Institut National de la Santé et de la recherche Médicale UMR-S 1178 Santé Mentale et Santé Publique Châtenay-Malabry France Denis J. David Univ. Paris-Sud, Fac Pharmacie, Université Paris Saclay Institut National de la Santé et de la recherche Médicale UMR-S 1178 Santé Mentale et Santé Publique Châtenay-Malabry France Dominique Matthys University of Montreal Hospital Research Center (CRCHUM); Departments of Nutrition; Neuroscience University of Montreal Donatella Marazziti Dipartimento di Medicina Clinica e Sperimentale, Section of Psychiatry University of Pisa Pisa Italy Federico Mucci Dipartimento di Medicina Clinica e Sperimentale, Section of Psychiatry University of Pisa Pisa Italy George Anderson CRC Scotland & London, Eccleston Square London UK Gerard Sanacora Yale University School of Medicine New Haven, CT USA Gianluca Serafini Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry University of Genoa Italy Gislaine Z. Réus Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit University of Southern Santa Catarina Criciúma, SC Brazil Goutam Brahmachari Department of Chemistry, Visva-Bharati University Santiniketan-731 235 Laboratory of Natural Products & Organic Synthesis West Bengal India Helena M. Abelaira Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina Criciúma, SC Brazil Jane A. Foster Department of Psychiatry & Behavioural Neurosciences @ St. Joseph's Healthcare Hamilton Jerad Suresh Department of Pharmaceutical Chemistry, College of Pharmacy, Madras Medical College Chennai India João Quevedo Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit University of Southern Santa Catarina Criciúma, SC Brazil Léa Décarie-Spain University of Montreal Hospital Research Center (CRCHUM); Departments of Nutrition; Neuroscience University of Montreal Liliana Dell’Osso Dipartimento di Medicina Clinica e Sperimentale, Section of Psychiatry University of Pisa Pisa Italy Manuela P. Kaster Department of Biochemistry, Center of Biological Sciences Universidade Federal de Santa Catarina, Campus Universitário Florianópolis, SC Brazil Mario Amore Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry University of Genoa Italy Mary Kay Lobo Department of Anatomy and Neurobiology Mary Kay Lobo, Assistant Professor, University of Maryland School of Medicine Baltimore, MD USA Michael Maes Deakin University, Department of Psychiatry Geelon Australia Morgana Moretti Nutrition Post-Graduate Program, Universidade Federal de Santa Catarina, Campus Universitário Florianópolis, SC Brazil Paolo Girardi Department of Neuroscience, Mental Health and Sensory Organs – Sant’Andrea Hospital Sapienza University of Rome Italy Renato T. Ramos Laboratory of Psychophysiology and Virtual Reality (LIM-23) Department of Psychiatry Faculty of Medicine, University of São Paulo Brazil Roger S. McIntyre University of Toronto, University Health Network, Mood Disorders Psychopharmacology Unit Toronto, Ontario Canada Stefano Baroni Dipartimento di Medicina Clinica e Sperimentale, Section of Psychiatry University of Pisa Pisa Italy Stephanie E. Fulton University of Montreal Hospital Research Center (CRCHUM); Departments of Nutrition; Neuroscience, University of Montreal; Montreal Diabetes Research Centre Montreal, QC Canada Yena Lee University of Toronto, University Health Network, Mood Disorders Psychopharmacology Unit Toronto, Ontario Canada Young Sup Woo Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of University of Toronto, University Health Network, Mood Disorders Psychopharmacology Unit Toronto, Ontario Canada |
Advertisement
|
||
| Webmaster Contact: info@benthamscience.net | Copyright © 2019 Bentham Science |